

# Henning Grønbeik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1915941/publications.pdf>

Version: 2024-02-01

293  
papers

14,233  
citations

36299

51  
h-index

26610

107  
g-index

300  
all docs

300  
docs citations

300  
times ranked

16102  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 43-50.	2.5	7
2	A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup> Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 376-383.	5.0	6
3	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
4	The galactose elimination capacity test to monitor liver disease course in patients with Wilson's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-6.	1.5	1
5	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-Y gastric bypass. <i>Physiological Reports</i> , 2022, 10, e15157.	1.7	3
6	The NAFLD/MAFLD debate: Is there a Consensus? Consensus methodology?. <i>Liver International</i> , 2022, 42, 742-748.	3.9	15
7	Highly Increased Levels of Interleukin-1 Inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 796-802.	1.4	3
8	Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study. <i>International Journal of Circumpolar Health</i> , 2022, 81, 2065755.	1.2	3
9	Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center. <i>Journal of Clinical Medicine</i> , 2022, 11, 2271.	2.4	0
10	Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis. <i>World Journal of Hepatology</i> , 2022, 14, 827-845.	2.0	0
11	Prognosis of Patients with Bronchopulmonary Neuroendocrine Neoplasms in a Tertiary Neuroendocrine Tumor Centre of Excellence. <i>Neuroendocrinology</i> , 2022, 112, 1214-1224.	2.5	1
12	The presence of interferon affects the progression of non-alcoholic fatty liver disease. <i>Genes and Immunity</i> , 2022, 23, 157-165.	4.1	2
13	Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	4
14	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. <i>Neuroendocrinology</i> , 2021, 111, 883-894.	2.5	54
15	A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021, 111, 840-849.	2.5	8
16	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute/chronic liver failure and acute decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 240-248.	2.8	11
17	Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 236-244.	2.0	7
18	Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 51-64.	3.0	8

#	ARTICLE	IF	CITATIONS
19	Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 289-297.	1.5	11
20	No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00306.	2.5	12
21	Interferon lambda 4 genotype and pathway in alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 304-311.	1.5	0
22	Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease. <i>Current Obesity Reports</i> , 2021, 10, 125-133.	8.4	11
23	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00315.	2.5	10
24	Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 376.	2.6	7
25	Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. <i>Cell Systems</i> , 2021, 12, 432-445.e7.	6.2	12
26	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , 2021, 60, 931-941.	1.8	32
27	P316 Human neutrophil elastase derived fragment of calprotectin (S100a9) is a serum biomarker (CPa9-HNE) for monitoring of anti-TNF± treatment response in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S342-S343.	1.3	0
28	Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 320-328.	3.7	9
29	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	7.3	102
30	Editorial: metformin for portal hypertension—old dog, new tricks? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 347-347.	3.7	0
31	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. <i>European Journal of Endocrinology</i> , 2021, 185, 23-32.	3.7	2
32	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single-Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1329-1336.	4.7	11
33	Cognitive impairment in stable Wilson disease across phenotype. <i>Metabolic Brain Disease</i> , 2021, 36, 2173-2177.	2.9	4
34	A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. <i>EJNMMI Research</i> , 2021, 11, 84.	2.5	1
35	The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNF± Treatment in Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 59-66.	2.2	10
36	Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome—a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 821-829.	3.7	12

#	ARTICLE	IF	CITATIONS
37	Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 217-224.	2.5	25
38	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 963-973.e14.	4.4	77
39	Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2020, 27, 28-35.	2.0	36
40	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
41	Thrombophilia testing in patients with portal vein thrombosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 694-698.	1.2	3
42	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3213.	2.4	14
43	Macrophage markers and innate immunity in cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 1586-1588.	3.7	8
44	Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer. <i>The Cochrane Library</i> , 2020, , .	2.8	0
45	Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00217.	2.5	16
46	TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1433-1440.	1.5	28
47	Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G151-G156.	3.4	2
48	Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 927-928.	3.7	5
49	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2
50	Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 588-596.	1.5	9
51	Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. <i>Cells</i> , 2020, 9, 1175.	4.1	89
52	Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. <i>Autoimmunity</i> , 2020, 53, 253-260.	2.6	9
53	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. <i>Alcohol</i> , 2020, 87, 29-37.	1.7	4
54	Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2020, 10, e035284.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 340-350.	3.7	16
56	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2020, 20, 210.	2.0	47
57	The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 173.	2.7	6
58	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	1.3	1,840
59	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
60	The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. <i>Trends in Genetics</i> , 2020, 36, 429-441.	6.7	58
61	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1408-1414.	3.9	22
62	A Comparison of free Chromogranin A Assays in Patients with Neuroendocrine Tumours. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 419-424.	0.9	12
63	Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. <i>Frontiers in Medicine</i> , 2020, 7, 615599.	2.6	19
64	PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. <i>PLoS ONE</i> , 2020, 15, e0243900.	2.5	11
65	Liver-related effects of chronic hepatitis C antiviral treatment. <i>World Journal of Gastroenterology</i> , 2020, 26, 2931-2947.	3.3	11
66	New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report. <i>World Journal of Gastroenterology</i> , 2020, 26, 550-561.	3.3	18
67	SAT-025 Increased Occurrence of Anemia, Gastrointestinal and Liver Diseases in Women with Turner Syndrome - a Nationwide Registry Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
68	Preemptive TIPSS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	7.3	144
69	Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis. <i>Journal of Diabetes Investigation</i> , 2019, 10, 67-72.	2.4	9
70	The role of IFN in the development of NAFLD and NASH. <i>Cytokine</i> , 2019, 124, 154519.	3.2	31
71	SAT-241-The dynamics of two plasma markers of type III collagen formation and degradation in the course of chronic hepatitis C viral clearance with direct-acting antiviral therapy. <i>Journal of Hepatology</i> , 2019, 70, e738.	3.7	0
72	FRI-016-Validation of the PRESto machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e390-e391.	3.7	2

#	ARTICLE	IF	CITATIONS
73	Use of biologically based complementary medicines in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 998-1002.	1.5	0
74	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	3.7	128
75	Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. <i>EBioMedicine</i> , 2019, 46, 444-451.	6.1	19
76	P282 Combination of biomarkers reflecting type IV collagen degradation and citrullinated vimentin predicts response to adalimumab with high diagnostic accuracy, in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S239-S240.	1.3	0
77	Su2013 " Effects of Glepaglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Analog, on Activation of Liver Macrophages and Gut Integrity in Patients with Short Bowel Syndrome. <i>Gastroenterology</i> , 2019, 156, S-690-S-691.	1.3	0
78	FRI-007-Serum markers of macrophage activation CD163 and Mannose receptor predict transplant-free survival in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e385-e386.	3.7	0
79	Tu1816 " Combination of Biomarkers Reflecting Type Iv Collagen Degradation and Citrullinated Vimentin Predicts Response to Adalimumab with High Accuracy, in Patients with Crohn's Disease. <i>Gastroenterology</i> , 2019, 156, S-1135.	1.3	0
80	SAT-240-Metabolic liver function improves 12 weeks after successful sofosbuvir-based direct-acting antiviral therapy in patients with chronic hepatitis C and advanced liver disease. <i>Journal of Hepatology</i> , 2019, 70, e738.	3.7	0
81	PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS. <i>Journal of Hepatology</i> , 2019, 70, e17-e18.	3.7	0
82	FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e385.	3.7	0
83	The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms. <i>Journal of Leukocyte Biology</i> , 2019, 106, 1129-1138.	3.3	38
84	551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB95.	1.0	0
85	Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver " a human galactose positron emission tomography study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 84-92.	3.7	7
86	FRI-120-Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension. <i>Journal of Hepatology</i> , 2019, 70, e439-e440.	3.7	0
87	Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 623-632.	1.5	7
88	THU-281-Single nucleotide polymorphisms associated with no interferon lambda 4 production are associated with reduced mortality in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2019, 70, e286.	3.7	0
89	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. <i>World Journal of Hepatology</i> , 2019, 11, 138-149.	2.0	122
90	Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1761-1770.	2.4	19

#	ARTICLE	IF	CITATIONS
91	Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 551-560.	1.5	29
92	FRI-339-Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e544.	3.7	0
93	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 145-159.	17.8	571
94	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G462-G472.	3.4	162
95	The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark. <i>Growth Hormone and IGF Research</i> , 2019, 44, 33-42.	1.1	13
96	Orchestration of Tryptophan Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	7.3	80
97	The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 302-311.	0.9	6
98	Effects of Implementation of a National Fast Track Clinical Pathway for Hepatocellular Carcinoma in Western Denmark. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 83-88.	0.9	5
99	Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms Tumor in Childhood. <i>Case Reports in Gastroenterology</i> , 2018, 12, 56-62.	0.6	2
100	Nutritional status and nutritional risk in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 284-292.	1.5	27
101	Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 657-664.	3.7	47
102	Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 305-311.	1.5	15
103	Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial. <i>Endocrine Connections</i> , 2018, 7, 107-114.	1.9	16
104	Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome. <i>Journal of Hepatology</i> , 2018, 68, S700.	3.7	0
105	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). <i>Medical Oncology</i> , 2018, 35, 47.	2.5	13
106	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 484-491.	2.8	27
107	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002.	7.3	76
108	Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 422-430.	1.5	26

#	ARTICLE	IF	CITATIONS
109	Time course of compromised urea synthesis in patients with alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 592-597.	1.5	7
110	P196 Serum biomarkers reflecting tissue-remodelling correlates with the simple endoscopic score for Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S197-S197.	1.3	0
111	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 67, 635-642.	1.8	10
112	High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 169.	2.7	7
113	No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neopeptide collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. <i>PLoS ONE</i> , 2018, 13, e0203200.	2.5	6
114	Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections. <i>Journal of Hepatology</i> , 2018, 68, S253-S254.	3.7	4
115	The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality. <i>Journal of Hepatology</i> , 2018, 68, S120-S121.	3.7	0
116	β-Blockers Improve Presinusoidal Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3153-3157.	2.3	10
117	Epigenetic modification of urea cycle enzymes in NAFLD animal models and patients: Implications for novel therapeutic approaches. <i>Journal of Hepatology</i> , 2018, 68, S359-S360.	3.7	0
118	The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease. <i>Journal of Hepatology</i> , 2018, 68, S631.	3.7	1
119	Urea cycle dysregulation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 905-915.	3.7	123
120	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 986-993.	1.5	23
121	Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients. <i>Journal of Hepatology</i> , 2018, 68, S541.	3.7	0
122	Combinations of inflammatory markers, soluble (s)CD163, mannose receptor (sMR) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2018, 68, S239.	3.7	0
123	The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study. <i>Neuroendocrinology</i> , 2018, 107, 280-283.	2.5	1
124	No effect of resveratrol on VLDL-C kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2504-2509.	4.4	29
125	Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2018, 13, e0192728.	2.5	7
126	Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2018, 10, 8-21.	2.0	13



#	ARTICLE	IF	CITATIONS
127	Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 4, 50-61.	4.1	61
128	Long-Term Ethanol Exposure Decreases the Endotoxin-Induced Hepatic Acute Phase Response in Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 562-570.	2.4	3
129	IFN- $\gamma$ 3, not IFN- $\gamma$ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	21.4	86
130	Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1682-1689.	1.0	46
131	A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2017, 24, 427-443.	3.1	49
132	Enrichment of Genetic Variants in the Glucocorticoid Receptor Signalling Pathway in Autoimmune Hepatitis with Failure of Standard Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 189-194.	2.5	5
133	Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population-based study. <i>Liver International</i> , 2017, 37, 1042-1046.	3.9	23
134	Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls. <i>International Journal of Obesity</i> , 2017, 41, 262-267.	3.4	24
135	A descriptive cross-sectional study of pain in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 431-436.	1.5	2
136	Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1652-1664.	10.7	108
137	Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 498-504.	1.2	26
138	Letter: autoimmune hepatitis drug-induced liver injury must always be excluded. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 384-384.	3.7	1
139	Isolated congenital hepatic fibrosis associated with <i>TMEM67</i> mutations: report of a new genotype-phenotype relationship. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1098-1102.	0.5	8
140	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 308-316.	0.9	0
141	High burden of coronary atherosclerosis in patients with cirrhosis. <i>European Journal of Clinical Investigation</i> , 2017, 47, 565-573.	3.4	14
142	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. <i>Liver International</i> , 2017, 37, 694-699.	3.9	178
143	Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 93-99.	1.5	40
144	The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation. <i>Liver International</i> , 2017, 37, 569-575.	3.9	12

#	ARTICLE	IF	CITATIONS
145	Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. <i>Acta Dermato-Venereologica</i> , 2017, 97, 426-432.	1.3	41
146	The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients. <i>PLoS ONE</i> , 2017, 12, e0189345.	2.5	32
147	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 321-348.	0.1	1
148	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. <i>PLoS ONE</i> , 2017, 12, e0187667.	2.5	24
149	Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 264-271.	2.4	4
150	Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 668-675.	2.8	14
151	The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1222-1231.	3.7	34
152	The damage-associated molecular pattern HMGB1 is elevated in human alcoholic hepatitis, but does not seem to be a primary driver of inflammation. <i>Apmis</i> , 2016, 124, 741-747.	2.0	15
153	Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1242-1252.	3.7	29
154	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.	12.8	104
155	Single-centre experience of the macrophage activation marker soluble (s)CD163 associations with disease activity and treatment response in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1062-1070.	3.7	33
156	Editorial: measuring inflammatory and fibrotic components of portal hypertension – a non-invasive hepatic venous pressure gradient? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 205-206.	3.7	0
157	The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1549-1557.	3.9	94
158	Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center. <i>Acta Radiologica</i> , 2016, 57, 844-851.	1.1	6
159	Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children. <i>European Journal of Clinical Nutrition</i> , 2016, 70, 1073-1077.	2.9	13
160	Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 456-464.	1.5	109
161	Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2016, 64, 813-822.	3.7	104
162	Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1637-1646.	3.6	26

#	ARTICLE	IF	CITATIONS
163	Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1721-1728.	1.5	73
164	Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 64-73.	1.2	29
165	Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. <i>Acta Oncologica</i> , 2016, 55, 3-14.	1.8	15
166	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2016, , 1-28.	0.1	2
167	Alcoholic Hepatitis Markedly Decreases the Capacity for Urea Synthesis. <i>PLoS ONE</i> , 2016, 11, e0158388.	2.5	20
168	Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats. <i>World Journal of Hepatology</i> , 2016, 8, 726.	2.0	22
169	Reply. <i>Hepatology</i> , 2015, 61, 735-736.	7.3	4
170	Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients. <i>PLoS ONE</i> , 2015, 10, e0117627.	2.5	26
171	Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with $^{90}\text{Y}$ -DOTATOC: Associations with Risk Factors. <i>Current Radiopharmaceuticals</i> , 2015, 8, 49-55.	0.8	8
172	Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 454-461.	1.5	4
173	The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. <i>Growth Hormone and IGF Research</i> , 2015, 25, 174-181.	1.1	17
174	Effect of resveratrol on experimental non-alcoholic steatohepatitis. <i>Pharmacological Research</i> , 2015, 95-96, 34-41.	7.1	33
175	Macrophage activation marker soluble $\text{CD}163$ and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1293-1300.	2.8	53
176	The macrophage activation marker $\text{CD}163$ is associated with changes in $\text{NAFLD}$ and metabolic profile during lifestyle intervention in obese children. <i>Pediatric Obesity</i> , 2015, 10, 226-233.	2.8	52
177	Circulating mannan-binding lectin, $\text{M}\alpha\text{2}$ , $\text{H}\alpha\text{1}$ and collectin $\text{CL}1$ levels in patients with acute liver failure. <i>Liver International</i> , 2015, 35, 756-763.	3.9	20
178	Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2015, 10, e0137302.	2.5	54
179	Trefoil factors in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 3223.	3.3	85
180	Vitamin $\text{B}_{12}$ and its binding proteins in hepatocellular carcinoma and chronic liver diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1096-1102.	1.5	23

#	ARTICLE	IF	CITATIONS
181	Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. <i>Liver International</i> , 2014, 34, 1584-1592.	3.9	13
182	Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. <i>Hepatology</i> , 2014, 60, 521-530.	7.3	150
183	Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014, 6, 188.	2.0	51
184	Prednisolone but Not Infliximab Aggravates the Upregulated Hepatic Nitrogen Elimination in Patients with Active Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 7-13.	1.9	7
185	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , 2014, 53, 1284-1297.	1.8	99
186	Soluble CD163, a Specific Macrophage Activation Marker, is Decreased by Anti-TNF Antibody Treatment in Active Inflammatory Bowel Disease. <i>Scandinavian Journal of Immunology</i> , 2014, 80, 417-423.	2.7	30
187	Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G295-G301.	3.4	44
188	Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 1749-1756.	0.4	81
189	Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center. <i>Indian Journal of Gastroenterology</i> , 2014, 33, 322-329.	1.4	6
190	Effects of long-acting somatostatin analogues on redox systems in rat lens in experimental diabetes. <i>International Journal of Experimental Pathology</i> , 2014, 95, 95-100.	1.3	0
191	Quantitative histological assessment of hepatic ischemia-reperfusion injuries following ischemic pre- and post-conditioning in the rat liver. <i>Journal of Surgical Research</i> , 2013, 180, e11-e20.	1.6	18
192	Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 969-973.	1.5	7
193	Regulation of urea synthesis during the acute-phase response in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G680-G686.	3.4	15
194	No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion. <i>Liver International</i> , 2013, 33, 1309-1315.	3.9	19
195	Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease. <i>Archives of Physiology and Biochemistry</i> , 2013, 119, 202-208.	2.1	7
196	Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. <i>Gut</i> , 2013, 62, 1231-1232.	12.1	40
197	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. <i>Annals of Oncology</i> , 2013, 24, 152-160.	1.2	792
198	Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course. <i>PLoS ONE</i> , 2013, 8, e55101.	2.5	26

#	ARTICLE	IF	CITATIONS
199	Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability. <i>Scientific World Journal, The</i> , 2013, 2013, 1-6.	2.1	23
200	Goblet Cell Carcinoids of the Appendix. <i>Scientific World Journal, The</i> , 2013, 2013, 1-6.	2.1	35
201	Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt. <i>World Journal of Hepatology</i> , 2013, 5, 38.	2.0	21
202	Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel <sup>®</sup> given by either self/partner or a health care professional. <i>Patient Preference and Adherence</i> , 2012, 6, 703.	1.8	20
203	Insulin-like Growth Factor-I Concentration and Risk of Prostate Cancer: Results from the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1531-1541.	2.5	67
204	Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. <i>British Journal of Cancer</i> , 2012, 106, 1004-1010.	6.4	51
205	Effect of a 10-week Weight Loss Camp on Fatty Liver Disease and Insulin Sensitivity in Obese Danish Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 223-228.	1.8	73
206	Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis. <i>Metabolic Brain Disease</i> , 2012, 27, 559-565.	2.9	28
207	Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism. <i>Clinical Nutrition</i> , 2012, 31, 940-945.	5.0	17
208	Carvedilol or propranolol in portal hypertension? A randomized comparison. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 467-474.	1.5	47
209	Ischemic pre- and postconditioning has pronounced effects on gene expression profiles in the rat liver after ischemia/reperfusion. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G482-G489.	3.4	15
210	Small intestinal transit in patients with liver cirrhosis and portal hypertension: a descriptive study. <i>BMC Gastroenterology</i> , 2012, 12, 176.	2.0	17
211	Creation of a Fistula Between the Hepatic Duct and the Gastric Lumen by way of Percutaneous Transhepatic Cholangiography: A Case Report. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 354-357.	1.3	0
212	Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes. <i>International Journal of Experimental Pathology</i> , 2012, 93, 56-69.	1.3	4
213	Effects of long-term experimental diabetes on adrenal gland growth and phosphoribosyl pyrophosphate formation in growth hormone-deficient dwarf rats. <i>International Journal of Experimental Pathology</i> , 2012, 93, 196-201.	1.3	2
214	Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1336-1342.	3.7	55
215	Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 173-180.	3.7	132
216	A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>Annals of Human Biology</i> , 2011, 38, 194-202.	1.0	72

#	ARTICLE	IF	CITATIONS
217	Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 197-200.	1.5	7
218	IL-6 has no acute effect on the regulation of urea synthesis in vivo in rats. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 150-156.	1.2	7
219	Prognosis and staging of non-alcoholic fatty liver disease. <i>BMJ: British Medical Journal</i> , 2011, 343, d7302-d7302.	2.3	8
220	Unchanged capacity of urea synthesis during acute phase response in rats. <i>European Journal of Clinical Investigation</i> , 2011, 41, 16-22.	3.4	2
221	Effects of ischemic pre- and postconditioning on HIF-1 $\alpha$ , VEGF and TGF- $\beta$ 2 expression after warm ischemia and reperfusion in the rat liver. <i>Comparative Hepatology</i> , 2011, 10, 3.	0.9	25
222	Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 895-902.	1.5	19
223	Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. <i>Gut</i> , 2011, 60, 1389-1393.	12.1	111
224	Peptide Receptor Radionuclide Therapy with $^{90}\text{Y}$ -DOTATOC and $^{177}\text{Lu}$ -DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland. <i>Neuroendocrinology</i> , 2011, 93, 189-196.	2.5	122
225	Serum levels of IGF-1, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. <i>International Journal of Cancer</i> , 2010, 126, 1702-1715.	5.1	190
226	Expression of genes involved in rat liver angiogenesis after ischaemia and reperfusion: effects of ischaemic pre- and post-conditioning. <i>Hpb</i> , 2010, 12, 554-560.	0.3	9
227	Ascites from patients with alcoholic liver cirrhosis contains higher IGF-1 bioactivity than serum. <i>Clinical Endocrinology</i> , 2010, 72, 625-632.	2.4	18
228	Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children. <i>European Journal of Endocrinology</i> , 2010, 163, 895-900.	3.7	28
229	Partial Liver Ischemia Is Followed by Metabolic Changes in the Normally Perfused Part of the Liver during Reperfusion. <i>European Surgical Research</i> , 2010, 45, 61-67.	1.3	2
230	Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. <i>Acta Oncologica</i> , 2010, 49, 740-756.	1.8	66
231	Insulin sensitivity and body composition in cirrhosis: changes after TIPS. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G486-G493.	3.4	17
232	Tumor necrosis factor- $\alpha$ acutely up-regulates urea synthesis in vivo in rats – a hepatic component of inflammatory catabolism?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 151-157.	1.2	10
233	Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2010, 16, 348.	3.3	35
234	Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections. <i>World Journal of Hepatology</i> , 2010, 2, 221.	2.0	2

#	ARTICLE	IF	CITATIONS
235	Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case-Control Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 96-101.	0.4	385
236	Cytokine Changes during Warm Ischemia and Reperfusion of the Pig Liver with or without Preconditioning. <i>European Surgical Research</i> , 2009, 42, 216-222.	1.3	12
237	The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis. <i>European Journal of Endocrinology</i> , 2009, 160, 957-963.	3.7	17
238	The Association between Diet and Serum Concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1333-1340.	2.5	121
239	The influence of preconditioning on metabolic changes in the pig liver before, during, and after warm liver ischemia measured by microdialysis. <i>Hepatology International</i> , 2009, 3, 310-315.	4.2	12
240	Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. <i>Growth Hormone and IGF Research</i> , 2009, 19, 426-431.	1.1	4
241	Metabolic Changes in the Pig Liver During Warm Ischemia and Reperfusion Measured by Microdialysis. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 319-326.	1.7	21
242	Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: A Danish population-based case-control study. <i>BMC Gastroenterology</i> , 2008, 8, 16.	2.0	66
243	Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 705-711.	3.0	35
244	Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1121-1127.	2.5	88
245	Effects of five different alcoholic drinks on patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 968-972.	1.5	24
246	The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 464-470.	1.5	29
247	Impact of Enteral Supplements Enriched with $\omega$ -3 Fatty Acids and/or $\omega$ -6 Fatty Acids, Arginine and Ribonucleic Acid Compounds on Leptin Levels and Nutritional Status in Active Crohn's Disease Treated with Prednisolone. <i>Digestion</i> , 2007, 75, 10-16.	2.3	17
248	The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: Relations to disease activity and corticosteroid treatment. <i>Growth Hormone and IGF Research</i> , 2007, 17, 33-40.	1.1	29
249	Soluble CD163 from activated macrophages predicts mortality in acute liver failure. <i>Journal of Hepatology</i> , 2007, 47, 671-676.	3.7	136
250	Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2007, 121, 368-376.	5.1	166
251	Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention. <i>BMC Gastroenterology</i> , 2007, 7, 1.	2.0	19
252	Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. <i>European Journal of Clinical Nutrition</i> , 2007, 61, 91-98.	2.9	129

#	ARTICLE	IF	CITATIONS
253	Opposite effects on regulation of urea synthesis by early and late uraemia in rats. <i>Clinical Nutrition</i> , 2007, 26, 245-251.	5.0	5
254	Discharge diagnoses of liver diseases in Nuuk Greenland compared to a Danish county hospital. <i>International Journal of Circumpolar Health</i> , 2006, 65, 162-168.	1.2	8
255	Associations between the IGF system and inflammatory markers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 553-554.	3.7	2
256	Quality improvement in wellness reports in patients with Crohn's disease. <i>Accreditation and Quality Assurance</i> , 2006, 11, 278-283.	0.8	2
257	Serum Trefoil Factors in Patients with Inflammatory Bowel Disease. <i>Digestion</i> , 2006, 74, 33-39.	2.3	42
258	Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1121-1128.	3.7	52
259	Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis. <i>BMC Gastroenterology</i> , 2005, 5, 31.	2.0	15
260	Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 1214-1221.	1.5	24
261	The Insulin-Like Growth Factor System and Markers of Inflammation in Adult Patients with Inflammatory Bowel Disease. <i>Hormone Research in Paediatrics</i> , 2005, 64, 9-15.	1.8	45
262	Effects of pure ethanol and alcohols on glucose, insulin, and the insulin-like growth factor system in healthy subjects. <i>Growth Hormone and IGF Research</i> , 2005, 15, 243-250.	1.1	6
263	Budd-Chiari and inferior caval vein syndromes due to membranous obstruction of the liver veins: successful treatment with angioplasty and transcaval transjugular intrahepatic porto-systemic shunt. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 1025-1028.	1.5	9
264	The Influence of Amphotericin B and Neomycin on the Effect of Human Relaxin-2 on Foetal Membranes and Isolated Myometrium. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 94, 144-150.	2.5	1
265	Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 594-599.	1.5	19
266	Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1759-64.	2.5	19
267	Markers of fetal growth and serum levels of insulin-like growth factor (IGF) I, -II and IGF binding protein 3 in adults. <i>European Journal of Epidemiology</i> , 2003, 19, 41-47.	5.7	12
268	Albumin in vaginal fluid is a marker of infection in early pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2003, 83, 307-308.	2.3	6
269	Effect of Combination Therapy with a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor on Renal Hypertrophy and Urinary Albumin Excretion in Diabetic Rats. <i>Experimental Diabetes Research</i> , 2003, 4, 191-199.	1.0	2
270	Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. <i>Anticancer Research</i> , 2003, 23, 2815-20.	1.1	10



#	ARTICLE	IF	CITATIONS
271	Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice. <i>Journal of Endocrinology</i> , 2002, 172, 637-643.	2.6	19
272	Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2002, 62, 39-47.	1.2	4
273	Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. <i>American Journal of Gastroenterology</i> , 2002, 97, 673-678.	0.4	14
274	Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2002, 62, 29-33.	1.2	100
275	Development and Evaluation of an ELISA for Human Trefoil Factor 3. <i>Clinical Chemistry</i> , 2002, 48, 1689-1695.	3.2	49
276	Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor $\beta^2$ receptor expression in experimental diabetes in rats. <i>Diabetologia</i> , 2001, 44, 495-500.	6.3	43
277	Effect of nitrendipine and nisoldipine on renal structure and function in long-term experimental diabetes in rats. <i>American Journal of Kidney Diseases</i> , 2000, 36, 368-377.	1.9	6
278	The Renal Expression of Transforming Growth Factor- $\beta$ Isoforms and Their Receptors in Acute and Chronic Experimental Diabetes in Rats. <i>Endocrinology</i> , 2000, 141, 1196-1208.	2.8	34
279	The Calcium Channel Blocker Nitrendipine Attenuates Renal and Glomerular Hypertrophy in Diabetic Rats. <i>Nephron Experimental Nephrology</i> , 1999, 7, 242-250.	2.2	14
280	Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion. <i>Journal of Hypertension</i> , 1999, 17, 973-981.	0.5	9
281	Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. <i>Kidney International</i> , 1998, 53, 173-180.	5.2	30
282	Effect of immunosuppression on kidney and serum insulin-like growth factor-I (IGF-I), IGF binding proteins, and renal growth following unilateral nephrectomy in rats. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 817-823.	3.4	8
283	Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. <i>Diabetes</i> , 1998, 47, 924-930.	0.6	22
284	Developmental Changes in Serum Levels of Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit in Rats**This work was supported by grants from the Danish Health Research Council (Grants 9602012 and 9700592), the Aarhus University-Novo Nordisk Center for Research in Growth and Regeneration (Danish Health Research Council Grant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	2.8	44
285	the Nordic Insulin Founda. <i>Endocrinology</i> , 1998, 139, 4286-4292. Diabetic kidney disease: the role of growth factors. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 1104-1107.	0.7	11
286	Effects of growth hormone on steroid-induced increase in ability of urea synthesis and urea enzyme mRNA levels. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 275, E79-E86.	3.5	15
287	Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats. <i>Diabetologia</i> , 1995, 38, 135-144.	6.3	19
288	Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes.. <i>Endocrinology</i> , 1995, 136, 1835-1842.	2.8	78

#	ARTICLE	IF	CITATIONS
289	The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 67-71.	3.4	35
290	Increased ornithine decarboxylase activity in kidneys undergoing hypertrophy in experimental diabetes. <i>Molecular and Cellular Endocrinology</i> , 1992, 86, 67-72.	3.2	15
291	Selenium in the central nervous system of rats exposed to <sup>75</sup> Se-selenomethionine and sodium selenite. <i>Biological Trace Element Research</i> , 1992, 35, 119-127.	3.5	18
292	Selenium complexes in the anterior pituitary of rats exposed to L-selenomethionine. <i>Vigiliae Christianae</i> , 1990, 59, 291-296.	0.1	0
293	Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer. <i>The Cochrane Library</i> , 0, , .	2.8	2